Adaptive Biotechnologies Corporation (ADPT) has a negative trailing P/E of -36.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 170.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.75%, forward earnings yield 0.59%.
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -99.2 | 0.00 | -18.92 | 110.51 | - |
| 2018 | -91.5 | -12.50 | -16.46 | 76.33 | - |
| 2019 | -54.2 | -7.95 | 6.51 | 43.73 | - |
| 2020 | -53.1 | -0.42 | 10.44 | 78.86 | - |
| 2021 | -19.0 | -0.50 | 6.52 | 25.52 | - |
| 2022 | -5.4 | 0.17 | 2.35 | 5.88 | - |
| 2023 | -3.1 | -0.06 | 2.29 | 4.15 | - |
| 2024 | -5.5 | 0.18 | 4.35 | 4.93 | - |
| 2025 | -41.4 | 0.65 | 11.26 | 8.90 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.41 | $38.45M | $-42.83M | -111.4% |
| 2018 | $-0.44 | $55.66M | $-46.45M | -83.4% |
| 2019 | $-0.85 | $85.07M | $-58.82M | -69.1% |
| 2020 | $-1.06 | $98.38M | $-139.64M | -141.9% |
| 2021 | $-1.46 | $154.34M | $-205.61M | -133.2% |
| 2022 | $-1.00 | $185.31M | $-142.46M | -76.9% |
| 2023 | $-1.56 | $170.28M | $-225.25M | -132.3% |
| 2024 | $-1.08 | $178.96M | $-159.49M | -89.1% |
| 2025 | $-0.39 | $276.98M | $-59.5M | -21.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.48 | $-0.50 – $-0.46 | $282.41M | $279.3M – $286.1M | 6 |
| 2027 | $-0.27 | $-0.29 – $-0.23 | $346.56M | $341.24M – $351M | 6 |
| 2028 | $-0.06 | $-0.29 – $0.06 | $415.16M | $415.11M – $415.2M | 4 |
| 2029 | $0.09 | $0.08 – $0.09 | $504.8M | $497.03M – $512.79M | 2 |
| 2030 | $-0.01 | $-0.01 – $-0.01 | $640.7M | $630.84M – $650.84M | 2 |
